ASCO Review: A Closer Look At Value By Tumor Type
ASCO's big push on providing value came through loud and clear in annual meeting sessions on multiple myeloma, breast cancer, colon cancer and renal cell carcinoma.
You may also be interested in...
Lead investigator says anti-38 antibody daratumumab compares well in earlier-stage relapsed disease to other myeloma drugs and advises using it early on the basis of "unprecedented" benefit.
Part 2: High costs are built into the rare disease business model. Participants at a roundtable discussion led by Scrip at the J.P. Morgan Healthcare Conference talked about how much they are feeling the pressure on pricing.
Part 1: Execs from rare disease-focused companies weighed in on investor sentiment during a roundtable discussion led by Scrip at the J.P. Morgan Healthcare Conference.